Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, appointed as Senior Vice President of Research and Development at OXcan

Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. The funding round was led by We Venture Capital and Cross-Border Impact Ventures with participation from return investors Eka Ventures, and Civilization Ventures, and new investors DigitalDx Ventures, Macmillan Cancer Support (Innovation Impact Investment Portfolio), Aurelium Ventures, OKG Capital, and prominent angel investors. This investment positions the company to develop and globally commercialize its new generation of minimally invasive liquid biopsy blood tests for the early detection of lung cancer.

OXcan has also appointed Dr. Heinrich Roder as Senior Vice President, Research & Development. With over two decades of experience in lung cancer liquid biopsy and commercialization, Dr. Roder will further advance OXcan’s lung cancer blood test for deployment.

OXcan’s protein-based blood test identifies molecular signatures for high-risk lung cancer patients, leveraging a diverse global biobank to ensure worldwide scalability. Using advanced proteomics and AI, it fills an unmet niche in the liquid biopsy space by offering a protein-based blood test with high accuracy to detect cancers with the highest mortality burden.

Since 2023, OXcan has formed global partnerships, collaborating with over 20 healthcare centers across three continents to develop and deploy its technology.

About Oxford Cancer Analytics

Oxford Cancer Analytics (OXcan) is on a mission to drastically transform cancer early detection and management to impact millions of lives worldwide. OXcan's multidisciplinary team is developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and explainable machine learning approaches that can detect the deadliest cancers early, when they can still be cured. This blood test can be conducted in an affordable, minimally invasive, and routine manner with superior accuracy and localization capacity in large populations. OXcan has applied their biomarker discovery and validation platform starting from lung cancer, the leading cause of cancer mortality worldwide, and achieved ISO13485 certification status. For additional information, visit oxcan.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109265837/en/

Media contact:
Jodi Echakowitz
Boulevard Public Relations
jodi@boulevardpr.com
+1 416-271-7250

Tags

More Like This

Cizzle Biotechnology announces North American licensing deal to launch revolutionary early lung cancer blood test in 2025

Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test

CIZZLE BIOTECHNOLOGY ANNOUNCES GROUNDBREAKING COLLABORATION WITH MOFFITT CANCER CENTER TO ADVANCE EARLY-STAGE LUNG CANCER DETECTION

Optellum showcases AI for precision lung cancer treatment at ASCO 2024

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

Immunovia successfully completes discovery phase of next-generation test development

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling